HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
Asia Biotech Live
LATEST UPDATES » Vol 24, No 01, January 2020 – Empowering the Patient - Personalization of Diabetes Management       » First of its kind Human Heart-in-a-Jar Model for therapeutic solutions       » China's National Vaccine Tracking System set to be completed in 2020       » China's amended drug administration law kicks in       » Human activity puts Chinese plant biodiversity at risk, study finds       » Contributory effects of each brain cell type in development of Alzheimer's Disease      
NEWS CRUNCH
Merck collaborates with Angiex to speed clinical readiness of new cancer therapy
Project is first for Merck's Massachusetts BioReliance End-to-End Solutions center. Collaboration gives Angiex access to Merck's process development tools and technologies.

Merck, a science and technology company, announced a new collaboration with Angiex, Inc., Cambridge, Massachusetts, USA to support the biotechnology start-up's ability to speed its lead oncology antibody drug candidate to clinical use. Angiex is developing an antibody-drug conjugate (ADC) therapy for cancer against a vascular target, TM4SF1.

The collaboration with Angiex is the first project to be undertaken at Merck's new biodevelopment center in Massachusetts, USA. Merck will give Angiex access to end-to-end process development tools, education programs and training to support its success.

"Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. "With an end-to-end approach, Merck can facilitate and accelerate scaling and technical transfer for companies like Angiex."

Angiex CEO Dr. Paul Jaminet applauded Merck's broad range of process development capabilities and services for customers at all stages of molecule development and commercialization. "Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate Merck's expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors," Jaminet said.

Merck's BioReliance? End-to-End Solutions deliver products and services allowing biopharmaceutical companies to accelerate the progression of potential new therapies from the laboratory into clinical trial and on toward commercialization. The turnkey package includes process development, cGMP manufacturing, facility design, equipment for pilot-plant production, process and equipment training, technology transfer, equipment qualification and set-up for commercialization. To further support its global BioReliance? End-to-End Solutions, Merck will inaugurate its new biodevelopment center in Burlington, Massachusetts in October 2017.

Merck's BioReliance? End-to-End Solutions is part of the Process Solutions business area within the Life Science business of Merck.

Source: Merck
NEWS CRUNCH  
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai
SPOTLIGHT  

MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy